180 Life Sciences Corp (ATNF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 180 Life Sciences Corp (ATNF) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.30 Million) by net assets ($445.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATNF net asset quality index to measure how much of total assets are equity-financed.
180 Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 180 Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 180 Life Sciences Corp cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
180 Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 180 Life Sciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Favored Nanotechnology Co. Ltd. A
SHG:688371
|
N/A |
|
Intellect Design Arena Limited
NSE:INTELLECT
|
0.027x |
|
Austal Ltd
AU:ASB
|
-0.047x |
|
Sky Gold Limited
NSE:SKYGOLD
|
-0.097x |
|
Nine Entertainment Co. Holdings Ltd
AU:NEC
|
-0.087x |
|
Ningbo Fujia Industrial Co Ltd
SHG:603219
|
0.020x |
|
Cinda Real Estate Co Ltd
SHG:600657
|
-0.002x |
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
0.182x |
Annual Cash Flow Conversion Efficiency for 180 Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of 180 Life Sciences Corp from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see ATNF stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -183.69% |
| 2018-12-31 | $-7.68 Million | $-789.23K | 0.103x | +2432.13% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more